# US 2023/0143825 A1 · A nanoparticle for use in the treatment of an ocular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0143825 A1
- Document ID: US20230143825A1
- Status: Published application
- Kind: A1
- Application number: 17/910,239
- Filed: 2021-03-11
- Published: 2023-05-11
- Earliest claimed: 2020-03-11
- Assignees: UniversitäT Regensburg
- Applicants: UniversitäT Regensburg
- Inventors: MARILENA BOHLEY; ACHIM GÖPFERICH
- Web page: https://patentgrep.com/patent/US20230143825A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 38/13: Cyclosporins
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a nanoparticle for use in the treatment of ocular diseases, in particular diseases of the retina (“retinopathies”) or of optic neuropathies, in particular glaucoma.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of effectively preventing or treating, in a patient, one or several of an inflammatory component, an immune-response component, an angiogenic component and a neurodegenerative component of a retinal disease or of an optic neuropathy; wherein said method comprises administering a nanoparticle to a patient in need thereof;
wherein said nanoparticle comprises:
a core comprising a drug that has one or several of the following activities: anti-inflammatory activity, immune-suppressive activity, anti-angiogenic activity, neuroprotective activity, gene therapeutic activity and regulatory activity on gene expression;
an amphiphilic shell surrounding said core, said amphiphilic shell comprising at least one phospholipid and, optionally, at least one surfactant;
a targeting ligand binding to a receptor expressed on the surface of retinal pigment epithelial (RPE) cells and/or endothelial cells and/or optic nerve cells; said targeting ligand being covalently coupled to said amphiphilic shell.

### Claim 17 (depends on 16)

The method according to claim 16, wherein effectively preventing or treating said one or several of an inflammatory component, an immune-response component, an angiogenic component, and a neurodegenerative component of said retinal disease or of said optic neuropathy manifests itself in one or several of:
an increase in intracellular availability of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells;
an extended residence time of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells;
an interference with the VEGF-signalling pathway in the eye;
a suppression or reduction of retinal neovascularization
a suppression or reduction of inflammation in the eye;
a suppression or reduction of an immune-response in the eye; and
a suppression or reduction of neurodegeneration and of neuronal cell death in the eye.

### Claim 18

The method according to claim i6, wherein said retinal disease is selected from retinal dystrophy and neovascular retinal diseases; and wherein said optic neuropathy is glaucoma.

### Claim 19 (depends on 17)

The method according to claim 17, wherein
said increase in intracellular availability of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells is an increase in intracellular availability of said drug in comparison to an intracellular availability of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells, observed when said drug is administered as a free drug that is not comprised within a nanoparticle; and/or
said extended residence time of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells, is a residence time of said drug in retinal pigment epithelial (RPE) cells and/or in optic nerve cells and/or in ocular endothelial cells, in the range of from at least 1 day-at least 5 days; and/or
said interference with the VEGF-signalling pathway in the eye is an inhibition of the expression or activity of the VEGF-receptor, or is an inhibition of the expression or activity of VEGF; and/or
said reduction of retinal neovascularization is a reduction of retinal neovascularization down to 50% or less of retinal neovascularization observed in an untreated retina affected by said retinal disease; and/or
said reduction of inflammation in the eye is a reduction of inflammation down to 50% or less of inflammation observed in an untreated eye affected by said retinal disease; and/or
said reduction of immune-response in the eye is a reduction of immune-response down to 50% or less of immune-response observed in an untreated eye affected by said retinal disease; and/or
said reduction of neurodegeneration and of neuronal cell death in the eye is a reduction of neuronal cell death down to 80% or more of the level of neuronal cell death observed in an untreated eye affected by said optic neuropathy.

### Claim 20 (depends on 16)

The method according to claim 16, wherein said receptor expressed on the surface of retinal pigment epithelial (RPE) cells and/or endothelial cells and/or optic nerve cells, is selected from a G-protein coupled receptor, an integrin, and a scavenger receptor.

### Claim 21 (depends on 16)

The method according to claim 16, wherein said drug that has one or several of anti-inflammatory activity, immune-suppressive activity, anti-angiogenic activity, neuroprotective activity, gene therapeutic activity and regulatory activity on gene expression is selected from anti-inflammatory drugs, immunesuppressive drugs, anti-angiogenic drugs, neuroprotective drugs, and nucleic acids.

### Claim 22 (depends on 21)

The method according to claim 21, wherein
said anti-inflammatory drugs are selected from glucocorticoids; COX-inhibitors; non-steroidal anti-inflammatory drugs (NSAIDs); anti-inflammatory prodrugs,; and activators of soluble guanylate cyclase (sGC);
said immune-suppressive drugs are selected from TNF-alpha inhibitors; Cyclosporins; mTOR-inhibitors; calcineurin inhibitors; inosinemonophosphate-dehydrogenasae inhibitors; folic acid antagonists; nitroimidazole-based immunesuppressants; and dihydro-orotate-dehydrogenase inhibitors;
said anti-angiogenic drugs are selected from inhibitors of VEGF-receptor (VEGFR) or of VEGF; antifungal drugs; folic acid antagonists; tyrosine kinase inhibitors; anti-diabetics; tricycle anti-depressants; statins; sartans; coumarine and coumarine derivatives; and IGF-1 receptor inhibitors;
said neuroprotective drugs are selected from immunosuppressant, anti-inflammatory and anti-oxidative drugs; and
said nucleic acids are selected from DNA, RNA, LNA, PNA, oligonucleotides of any of the foregoing.

### Claim 23 (depends on 16)

The method according to claim 16, wherein said nanoparticle is a lipid nanoparticle, and said shell comprises a phospholipid selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidic acid, phosphoinositides, phosphatidylinositol monophosphate, phosphatidylinositol bisphosphate, phosphatidylinositol triphosphate, ceramide phosphorylcholine, ceramide phosphorylethanolamine, ceramide phosphoryllipid and mixtures of any of the foregoing, and wherein said shell further comprises a surfactant.

### Claim 24 (depends on 16)

The method according to claim 16, wherein said core is
a) an oily core, and said drug is a lipohilic drug; or
b) an aqueous core, and said drug is a hydrophilic drug.

### Claim 25

The method according to claim i6, wherein said core comprises an oily or aqueous phase and said drug, said drug being dispersed in said oily or aqueous phase, said drug being dispersed in said oily or aqueous phase in the form of particles.

### Claim 26 (depends on 16)

The method according to claim 16, wherein said core comprises a solvent and said drug, said drug being dissolved or dispersed in said solvent, wherein is or comprises lipids, in particular mono-, di- or trigylcerides.

### Claim 27 (depends on 16)

The method according to claim 16, wherein said nanoparticle, in particular said lipid nanoparticle, has a size in the range of from 5 nm to 100 nm.

### Claim 28 (depends on 16)

The method according to claim 16, wherein said nanoparticle, when administered to a patient as a sample of a plurality of nanoparticles, shows an enrichment in at least one of blood, spleen and eyes of said patient, by a factor of >3, in comparison to nanoparticles without a targeting ligand binding to an integrin.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said nanoparticle, when administered to a patient as a sample of a plurality of nanoparticles, shows an enrichment in the eyes of said patient, wherein said enrichment occurs in the retinae of said eyes or in or at the optic nerve.

### Claim 30 (depends on 16)

The method according to claim 16, wherein, in said method of effectively preventing or treating one or several of an inflammatory component, an immune-response component, an angiogenic component, and a neurodegenerative component of said retinal disease or of said optic neuropathy, said nanoparticle is administered to a patient as a sample of a plurality of such nanoparticles, wherein such administration is performed as
a) a systemic administration selected from an intravenous administration, a subcutaneous administration, an intramuscular administration, a nasal administration, a pulmonal administration, more preferably an intravenous administration, or
b) a local administration selected from an intraocular administration, a subretinal administration, and an administration to the cornea, more preferably an intravitreal administration, even more preferably in the vicinity of the retina of the respective eye of said patient.

### Claim 31 (depends on 18)

The method according to claim 18, wherein the retina disease is selected from hereditary retinal dystrophy, and the glaucoma is open-angle glaucoma or angle-closure glaucoma.

### Claim 32 (depends on 20)

The method according to claim 20, wherein said integrin is selected from ανβ3-integrin and ανβ5-integrin, and wherein said targeting ligand is selected from a peptide having an amino acid sequence RGD, a cyclic peptide having an amino acid sequence of cyclo(-Arg-Gly-Asp-D-Phe-Cys) and derivatives thereof, or wherein said targeting ligand is a phospholipid.

### Claim 33 (depends on 23)

The method according to claim 23, wherein said surfactant is glycerol polyethylene glycol ricinoleate.

### Claim 34 (depends on 24)

The method according to claim 24, wherein said lipophic drug is selected from cyclosporine A; activators of soluble guanylate cyclase (sGC); glucocorticoids; statins; tacrolimus; Coenzyme Q10 (CoQ10); Vitamin E; citicoline; palmitoylethanolamide; melatonin; and SC79; and said hydrophilic drug is selected from anti-VEGF peptides and anti-VEGFR peptides; tricyclic anti-depressants; and growth factors.

### Claim 35 (depends on 26)

The method according to claim 26, wherein the fatty acid component(s) of said mono-, di- or tri-glycerides has(have) a chain length of fatty acids in the range of from 6-18 carbon atoms.
